Abstract:Tau aggregation measured with PET and neurodegeneration measured with MRI are closely associated with cognitive decline in Alzheimer's disease, but the independent contributions of baseline and longitudinal measures of these imaging markers to cognitive decline remain unclear. Here, we tested a) independent associations between baseline and rate of change in tau-PET or MRI and cognitive decline, b) relative contributions of baseline and rate of change in tau-PET or MRI vs cognitive decline and c) effects of simulated treatment-induced reductions of tau aggregation on cognitive trajectories. We included n=761 amyloid-positive individuals from the Swedish BioFINDER-2 study (n=253 cognitively unimpaired; n=508 cognitively impaired), with [18F]RO948-tau-PET, 3T structural MRI and cognition, including MMSE and a cognitive composite, of whom n=322 participants had longitudinal imaging data (n=120 cognitively unimpaired; n=202 cognitively impaired). Tau-PET SUVR and cortical thickness measures were quantified in entorhinal, amygdala (tau-PET only), inferior middle temporal, neocortical regions and hippocampal volume (MRI only). Associations between baseline or longitudinal imaging and longitudinal cognition were assessed using linear mixed models with random intercepts and slopes, adjusting for age, sex, education, diagnosis and the other imaging modality. Baseline and longitudinal tau-PET showed stronger associations with cognitive decline than MRI, with the strongest effects for inferior-middle-temporal and neocortical regions for baseline tau-PET (MMSE: inferior-middle-temporal: β=-0.18(0.01), p<0.001; neocortical: β=-0.17(0.01), p<0.001; cognitive-composite: inferior-middle-temporal: β=-0.22(0.02), p<0.001; neocortical: β=-0.25(0.02), p<0.001), and neocortical composite for longitudinal tau-PET (MMSE: β=-0.56(0.04), p<0.001; and cognitive-composite: β=-0.62(0.05), p<0.001). When correcting for the other imaging modality, associations for tau-PET showed smaller reductions than MRI at baseline (14.9% for tau-PET vs 46.7% for MRI). Serial mediation models showed that baseline tau-PET explained the largest proportion of cognitive decline (54.0-94.0%), with modest mediation effects for longitudinal tau-PET or MRI pathways (2.0-15.0%). Simulated treatment-induced partial reductions of tau aggregation showed marginal effects on cognitive trajectories (MMSE: placebo vs 70% slope reduction: βrate-of-change=0.35[0.18-0.53], p<0.001, placebo vs 50%: βrate-of-change=0.25[0.08-0.43], p<0.001, cognitive-composite: placebo vs 70%: βrate-of-change=0.10[0.04-0.16], p<0.001) compared to halting tau progression (MMSE: placebo vs no-progression: βrate-of-change=1.03[0.85-1.22], p<0.001, cognitive-composite: placebo vs no-progression: βrate-of-change=0.33[0.27-0.39], p<0.001). In conclusion, our results demonstrated the greater utility of tau-PET than MRI as a prognostic and disease monitoring marker, across the clinical spectrum of Alzheimer's disease. In addition, baseline tau load showed stronger associations with cognitive decline than tau progression. Furthermore, simulated treatment-induced reductions of tau progression showed limited effects on cognitive trajectories compared to halting tau progression and may point towards the need for early tau interventions.

Lower Locus Coeruleus Integrity Signals Elevated Entorhinal Tau and Clinical Progression in Asymptomatic Older Individuals

Spatiotemporal Assessment of Locus Coeruleus Integrity Predicting Cortical Tau and Cognition

Locus coeruleus metabolic changes as a predictor of tau accumulation and cognitive decline

In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer’s disease pathology and cognitive decline

Lower novelty-related locus coeruleus function is associated with Aβ-related cognitive decline in clinically healthy individuals

Association of Novelty-Related Locus Coeruleus Function With Entorhinal Tau Deposition and Memory Decline in Preclinical Alzheimer Disease

Elevated locus coeruleus metabolism provides resilience against cognitive decline in preclinical Alzheimer's disease

Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

Implementation and Assessment of Tau Thresholds in Non-Demented Individuals as Predictors of Cognitive Decline in Tau Imaging Studies

Elevated Tau PET Signal Depends on Abnormal Amyloid Levels and Correlates with Cognitive Impairment in Elderly Persons without Dementia

Lower novelty‐related locus coeruleus function is associated with entorhinal tau‐mediated memory decline in older individuals.

Dynamic associations between tau aggregation, atrophy, and cognitive decline in Alzheimer's disease

Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease

Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age

Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology

TAU ACCUMULATION IN RHINAL CORTEX IS ASSOCIATED WITH MEMORY PERFORMANCE IN NON-DEMENTED YOUNG ADULTS WITH AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE

Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients

Predicting future rates of tau accumulation on PET

Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease

MICROGLIAL ACTIVATION AND TAU BURDEN PREDICT COGNITIVE DECLINE IN ALZHEIMER’S DISEASE

Atrophy links lower novelty‐related locus coeruleus connectivity to cognitive decline in preclinical AD